IRVINE, CA, June 1, 2022 – Aracari Biosciences, Inc. (“Aracari”) announced that Dr. Chris Hughes, Chief Scientific Officer, will be speaking at BioInsights’ Immuno-Oncology Insights series on June 8th, 2022, titled “Life on a Chip – Vascularized Micro-Tumor Chips for Mimicking Clinical Drug Responses”.
Dr. Hughes will be speaking about Aracari’s cutting-edge organ chip technology already in use by several of the top pharmaceutical companies for drug development and immuno-oncology applications. Most cells in our body are no farther from a blood vessel than the width of a hair. Blood vessels help pattern tissues and provide them with their nutrients, and since almost all therapeutics — whether small molecules, antibodies, or leukocytes — reach our tissues via blood vessels, no model of tissue-drug interaction is realistic without this supporting vascular network. Dr. Hughes will share with the attendees what data are available in vitro for developing drug, cell and gene-based therapies, including:
- Continual imaging of tumor growth and response to drugs
- Imaging of leukocyte vascular adhesion & extravasation
- Assessment of tumor occupancy and killing by leukocytes, including CAR-Ts
- Assessment of monoclonal antibody & bispecific delivery and efficacy
- Assessment of target gene expression by in situ staining or qPCR
- Collection of venous outflow for assessment of biomarkers
“CAR-T and many other immune-oncology therapies are in great need for a human relevant in vitro system for drug development. We are very excited to be sharing with the BioInsights community of scientists about the power of Aracari’s vascularized tumor chip for predicting human responses in vivo,” says Dr. Hughes.
About Aracari Biosciences, Inc.
Aracari’s mission is to accelerate drug development and tailor treatments to individual patients by using the greater accuracy of its microphysiological platforms to predict drug reactions in humans. Aracari’s 3D Vascularized Micro-Organ and Micro-Tumor platforms incorporate living, perfused human vasculature to deliver nutrients, drugs and immune cells into the microenvironment of multiple tissue and tumor types, just as they are delivered in the human body. Aracari’s powerful next-generation tools already are advancing discovery in immuno-oncology therapies and drug development.
About BioInsights
Guided by pharma, biotech and academic editorial board, BioInsights and its Immuno-Oncology Insights share the learnings and insights of acknowledged, experienced industry experts and KOLs from across the field to help guide future approaches to addressing the myriad challenges the industry face.
Contact
Ming-I Huang
CEO
ming-i.huang@aracaribio.com
www.aracaribio.com
